Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, modified release - excipient ingredients: magnesium stearate; titanium dioxide; macrogol 400; light magnesium oxide; povidone; carrageenan; lactose monohydrate; iron oxide yellow; microcrystalline cellulose - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 345.39 mg (equivalent: quetiapine, qty 300 mg) - tablet, modified release - excipient ingredients: povidone; lactose monohydrate; light magnesium oxide; magnesium stearate; macrogol 400; microcrystalline cellulose; iron oxide yellow; carrageenan; titanium dioxide - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 57.565 mg (equivalent: quetiapine, qty 50 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; macrogol 400; microcrystalline cellulose; carrageenan; povidone; light magnesium oxide; titanium dioxide; iron oxide yellow; magnesium stearate; iron oxide red - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quetiapine fumarate, quantity: 172.695 mg (equivalent: quetiapine, qty 150 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; povidone; macrogol 400; titanium dioxide; light magnesium oxide; magnesium stearate; carrageenan - bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of quetiapine in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorde in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quetiapine fumarate, quantity: 345.45 mg (equivalent: quetiapine, qty 300 mg) - tablet, modified release - excipient ingredients: sodium chloride; purified talc; magnesium stearate; lactose monohydrate; hypromellose; povidone; titanium dioxide; iron oxide yellow; macrogol 400 - bipolar disorder,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dosage and administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,generalised anxiety disorder treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quetiapine fumarate, quantity: 460.6 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; sodium chloride; magnesium stearate; hypromellose; purified talc; povidone; titanium dioxide; macrogol 400 - bipolar disorder,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dosage and administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,generalised anxiety disorder treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quetiapine fumarate, quantity: 345.45 mg (equivalent: quetiapine, qty 300 mg) - tablet, modified release - excipient ingredients: povidone; purified talc; lactose monohydrate; sodium chloride; hypromellose; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - bipolar disorder,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dosage and administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,generalised anxiety disorder treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quetiapine fumarate, quantity: 460.6 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: hypromellose; lactose monohydrate; magnesium stearate; purified talc; povidone; sodium chloride; titanium dioxide; macrogol 400 - bipolar disorder,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dosage and administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,generalised anxiety disorder treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quetiapine fumarate, quantity: 460.6 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: magnesium stearate; lactose monohydrate; purified talc; hypromellose; povidone; sodium chloride; titanium dioxide; macrogol 400 - bipolar disorder,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dosage and administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,generalised anxiety disorder treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quetiapine fumarate, quantity: 230.3 mg (equivalent: quetiapine, qty 200 mg) - tablet, modified release - excipient ingredients: purified talc; lactose monohydrate; magnesium stearate; sodium chloride; hypromellose; povidone; titanium dioxide; iron oxide yellow; macrogol 400 - bipolar disorder,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dosage and administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,generalised anxiety disorder treatment of generalised anxiety disorder (gad).